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A human oncogene, mcJ3, previously detected by a combination of DNA-mediated gene transfer and a
tumorigenicity assay, derives from a human homolog of the avian v-ros oncogene. Both v-ros and mcJ3 can
encode a protein with homology to tyrosine-specific protein kinases, and both mcJ3 and v-ros encode a potential
transmembrane domain N terminal to the kinase domain. mcJ3 probably arose during gene transfer from a
normal human ros gene by the loss of a putative extracellular domain. There do not appear to be any other
gross rearrangements in the structure of mcf3.
Cellular oncogenes, which are genes capable of altering
the growth properties of normal cells, were first detected as
the homologs of transforming genes of RNA tumor viruses
(3). Additional cellular oncogenes have been discovered by
their amplification in certain tumor cells (12, 21) and by DNA
transfer techniques (1, 7, 14, 24). The most commonly used
assay for detecting oncogenes after DNA transfer has been
focus formation in NIH 3T3 cells (23). We have been
exploring an alternate assay for oncogenes based on
tumorigenicity in nude mice (4, 8). The details of the
procedure we use have been published previously (8). In
brief, DNA isolated from a tumor is cotransfected into NIH
3T3 cells in the presence of a G418 antibiotic resistance gene
(25, 31). Cells which have taken up foreign DNA are selected
by their resistance to G418, grown into colonies, pooled, and
injected into animals.
We previously described our studies of cotransformation
with DNA from the human mammary carcinoma cell line
MCF-7 (8). After cotransforming NIH 3T3 cells with this
DNA and injecting cotransformed cells into nude mice we
obtained three primary tumors, called MCF-7-1, MCF-7-2,
and MCF-7-3. DNA from each of these was capable of
efficiently inducing secondary tumors after another round of
cotransformation into NIH 3T3 cells and tumorigenicity
assays. The MCF-7-1 tumor, and subsequent tumors derived
from MCF-7-1 DNA, were shown to contain the human
N-ras gene. DNA from all tumors derived from MCF-7-2
DNA contained a common gene which we called mc;2: and
DNA from MCF-7-3 and its derived tumors all contained a
gene which we called mcj3. We previously described the
isolation of portions of tnu2 and mncJ3 (8). Here we report
the molecular characterization of mcj3. incj3 derives in part
from the closest human homolog of the avian v-ros oncogene
which we call rosl. The human rosl gene appears to have
been activated during gene transfer. We present the nucleo-
tide sequence of the activated gene. Based on the predicted
amino acid sequence, the human rosl gene, like the chicken
cellular ros gene (16), encodes a putative transmembrane
protein kinase, possibly a growth factor receptor.
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T Present address: U.119 institute National de la Sante et de la
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of Germany.
MATERIALS AND METHODS
Cell culture, cotransfection and tumorigenicity assays. NIH
3T3 cells at 8 x 105 cells per plate were cotransformed with
300 ng of pKOneo plasmid DNA (30) and 5 ,ug of each of the
cosmid fragments. The selection for G418 antibiotic resist-
ance and the tumorigenicity assay were performed as previ-
ously described (8). Cell cultures were established from
excised tumors after surgical removal and mincing and were
maintained in Dulbecco medium plus 10% calf serum under
our standard culture conditions. Nomenclature for tumors
and cell lines derived from them is as follows. Independent
secondary tumors and cell lines derived from MCF-7-3 DNA
are called MCF-7-3-n, where n is a number. Independent
tertiary tumors and cell lines derived from MCF-7-3-ni DNA
are called MCF-7-3-2-,n, where m is a number.
Construction of libraries. DNAs were prepared from tu-
mors or human placentas as previously described (8).
Genomic libraries were constructed from placental or MCF-
7-3-4 tumor DNAs by partial cleavage with EcoRI and
cloning into the cosmid vector pHC79 (10). Appropriate
fragments from a previously isolated bacteriophage lambda
library (8) were used for colony filter hybridization. Addi-
tional overlapping cosmid clones were then isolated by
hybridization with appropriate probes isolated from cosmid
clones. cDNAs were synthesized from poly(A)t mRNA
isolated from the nude mouse tumor-derived cell line MCF-
7-3-7 (13). The cDNA library was constructed into XgtlO
(11). Phages containing tnwf3 cDNAs were isolated by plaque
hybridization. initially with the EcoRl fragment 1.4 kilobase
pairs (kbp) in length isolated from cosmid clone 101 (see Fig.
1), and later with fragments isolated from cDNA clones.
DNA and RNA analysis. Southern blot analysis under high-
and low-stringency conditions was performed as previously
described (19, 24). DNA sequences were determined by the
dideoxy method of Sanger et al. (20) as modified by Biggin et
al. (2). Both strands of the coding sequences of the incj3
cDNA were sequenced. To localize the exon sequences, we
performed Southern analysis using cDNA fragments as
probes. A synthetic oligonucleotide with the sequence 5'-
CCAACTATAATAGTAAGTATG-3', which corresponds to
the noncoding strand of the sequences encoding amino acids
10 to 15, was used as probe to localize the exon encoding the
transmembrane domain. This oligonucleotide hybridized to
the EcoRI fragment 4.8 kbp in length and was used as a
primer for sequencing double-stranded DNA fragments from
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FIG. 1. Structure of mcf3 locus. The inserts of the cosmid clones isolated from MCF-7-3-4 tumor DNA are shown in the upper panel.
Numbers on the right are their identifiers. The EcoRI restriction sites deduced from the overlapping cosmid clones are shown by vertical lines,
and the length of relevant EcoRI fragments (in kilobase pairs) are depicted below. Where there is ambiguity of fragment order, the EcoRI sites
are designated with dashed vertical lines. The ClaI restriction sites are indicated by C. The darkened bars indicate regions of the mc]3 locus
composed of contiguous human DNA. The clear bar indicates the region of the mcJ3 locus of undetermined origin. The cosmids 101 and 209,
linearized at their unique SalI sites in the vector DNA, and the CIaI-ClaI fragment of cosmid 115 which were used for cotransfection and
reconstitution of an intact mcf3 locus are shown in the lower panel. Squiggly lines are cosmid vector sequences.
both placental and mcJ3 cosmid clones by a modification of
the dideoxy method (6). The oligonucleotides used in this
study were synthesized on an Applied Biosystems DNA
synthesizer and purified from polyacrylamide gels as de-
scribed previously (34). RNA was prepared from cell lines
by the guanidinium-hot phenol method (13) and analyzed on
Northern blots as described previously (27). RNA protection
studies with labeled DNA as hybridization probes were
performed as described previously (15).
RESULTS
Structure of the mcJ3 locus. We previously described a set
of Charon 4A phage clones containing portions of the mcJ3
locus (8). To obtain a complete set of clones from the mcJ3
locus, we chose to use the cosmid cloning vector pHC79 (10)
and constructed a cosmid library from the DNA of a sec-
ondary nude mouse tumor MCF-7-3-4. DNA sequences from
the Charon phages were used initially as probes to isolate
clones from the cosmid library. Overlapping cosmids were
cloned until we obtained clones which contained sequences
not found in all tumors derived by cotransformation with
DNA from MCF-7-3. An EcoRI map of this 70-kbp region is
depicted in Fig. 1. Only EcoRI fragments to the left and
including the 5.6-kbp fragment and to the right and including
the 0.4-kbp fragment were found in all mcJ3 transformants.
To demonstrate that we had cloned the entire transforming
gene and to determine the location of this gene in the
70-kbp-long stretch of cloned DNA, cosmid clones from
different regions of the mcJ3 locus were linearized at the
unique. Sall site in the cosmid vector and tested for their
ability to induce the tumorigenic phenotype in cotransfected
NIH 3T3 cells. None of the individually tested cosmids
scored positive in the assay, indicating that the transforming
gene extends over a major part of the mcJ3 locus. Similarly,
no pairwise combination of cosmids was able to induce
tumorigenicity in NIH 3T3 cells. Therefore, we performed
cotransformation experiments with three overlapping pieces
of DNA: two linearized cosmids and a third cosmid frag-
ment, which together span the whole locus. The pieces used
were cosmid clones 101 and 209, linearized at their unique
Sall sites, and the ClaI fragment of cosmid clone 115 (Fig. 1,
lower panel). The combination of all three fragments scored
positive in the cotransfection and tumorigenicity assay,
whereas no combination of two fragments did (data not
shown). Therefore, to form an intact mcf3 oncogene, two
homologous recombination events had to take place. This
shows that we cloned the entire mcJ3 oncogene. It is clearly
a very large gene, which may extend over nearly 70 kbp of
DNA.
To compare the structure of the mcJ3 locus with normal
cellular DNA, we constructed a cosmid library from human
placental DNA. Appropriate DNA fragments from the mcJ3
locus were used for screening this library, and five indepen-
dent cosmid clones were obtained. The DNAs present in
these clones could not be aligned over their full length with
the mcJ3 locus. Additional cloning and Southern analysis
indicated that the different structure of the placental cosmid
clones and the mcJ:3 locus was not an artifact of cosmid
cloning (data not shown). The mcJ3 locus was created by
DNA rearrangement involving the fusion of at least three
separate fragments of DNA. The first of these is a fragment
of human DNA located at what we later show to be the 5'
end of the mcfl oncogene, and it extends from the left end of
MOL. CELL. BIOL.
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the map of the mcj3 locus to the EcoRI fragment that is 3.7
kbp in length. This fragment is connected by DNA of
unknown origin to another fragment of the human genome
which contains the majority of the coding sequences of mcJ3.
The second piece of human DNA extends from the EcoRI
fragment that is 4.8 kbp in length to the right end of the map
of the mcf3 locus. The lengths and positions of these three
fragments are indicated in Fig. 1. The DNA rearrangements
which created the mc]3 locus are probably of functional
significance since they span the regions that were required in
the cotransfection studies described above.
Analysis and identification of mcJ3 oncogene. Since the
mcJ3 gene is large, cloning cDNAs to the transcript of the
mc.3 oncogene was necessary for the further analysis of the
gene. To localize the transcription unit in the mcf3 locus, we
analyzed poly(A)+ RNA from a cell line established from the
secondary nude mouse tumor MCF-7-3-7. We used various
fragments from the mcf3 locus as probes in Northern blots.
The 1.4-kbp EcoRI fragment contained in cosmid 101 (Fig. 1)
detected several RNA species of 2.8 to 3.3 kb in RNA from
MCF-7-3-7 cells (data not shown). These RNA species were
not found in RNA from normal NIH 3T3 cells. The EcoRI
fragment 1.4 kbp in length was then used as probe for
screening a cDNA library. The library was constructed by
cloning cDNAs synthesized from poly(A)+ RNA of the
MCF-7-3-7 cell line into the XgtlO cloning vector (11). The 3'
end of one transcript was localized in cDNA clone M3.9,
which contained a poly(A)+ tail. This also determined the
direction of transcription in the mcJ3 locus which was
subsequently verified by S1 mapping (data not shown).
Heterogeneity in the structure of the isolated cDNA
clones was revealed when they were hybridized to EcoRI
digests of mcJ3 DNA. The heterogeneity was confined to
sequences derived from the 5' end of the gene and indicated
that different splicing events occur at the 5' end of the mcf3
transcripts (data not shown). All the isolated cDNA clones
contained a portion with common structure which hybrid-
ized to a common set of EcoRI fragments from the mcf3
locus. These common sequences are transcribed from, and
completely contained within, the 3' portion of the locus
which derives from the long contiguous piece of human
DNA.
To obtain information about the nature of the mcf3 trans-
forming protein, we determined the sequence of the open
reading frame in the common portion of the mcf3 cDNAs.
These nucleotide sequences and the predicted amino acid
sequences are shown in Fig. 2. Initial computer analysis of
the amino acid sequence indicated that the mcf3 protein
sequence was similar to that of all oncogenes encoding
tyrosine kinases, but closely related to none. When the
sequence of v-ros, the transforming gene of the avian sar-
coma virus UR2, was published (17), it was immediately
obvious that the mcf3 protein was closely related to v-ros.
For comparison, the amino acid sequence of the v-ros
protein is shown in Fig. 3. From amino acid 51 to 370 of
mcfl, 75% homology exists between the two proteins. Only
at the C terminus do they differ considerably, where the
mc]3-encoded protein contains 99 additional amino acids not
found in the v-ros protein. The close homology between
v-ros and mcJ3 initially surprised us since in previous studies
we found that a fragment of the mcf3 gene, represented in
RNA transcripts, showed no homology to a panel of cloned
retroviral oncogenes which included v-ros (8). However, the
fragment of mcJ3 used in the earlier studies encodes the
C-terminal part of the rosi protein and has limited homology
to v-ros.
The close homology between the chicken-derived v-ros
gene and the common part of the mcf3 cDNAs suggests that
the 3' portion of the mcf3 locus derives from the human
counterpart of the v-ros gene. To determine whether this is
indeed the case, we performed Southern analyses of total
human DNA under conditions of low stringency with two
probes, a v-ros and an mcf3 cDNA fragment, which encode
roughly analogous sequences of the ros proteins. The probe
from the mcf3 cDNA hybridized most strongly to two EcoRI
fragments, 2.9 and 5.0 kbp, which correspond to two frag-
ments of human DNA known to contain exon sequences
(Fig. 4A, lanes 2 and 3). The v-ros probe hybridized most
strongly to an EcoRI fragment in human DNA 2.9 kbp in
length, corresponding to the same fragment of the mcf3 locus
(Fig. 4B, lanes 2 and 3). We conclude, therefore, that a major
portion of the mcf3 coding sequence is derived from the gene
in humans most closely related to the v-ros gene. We call this
gene rosi, since other human genes related to the v-ros or
the mcf3 gene may exist.
Potential membrane-spanning domain and rearrangement
of mcJ3 gene. Five of the oncogenes known to encode
oncogenic tyrosine kinases, v-ros (17), v-erbB (32), v-fms
(9), neu (1), and trk (14), have hydrophobic potential mem-
brane-spanning domains. The membrane-spanning domains
of these proteins are always encoded 5' to sequences encod-
ing the kinase domain. Inspection of the mcf3 nucleotide
sequence shows that it can encode a highly hydrophobic
stretch of 21 amino acids immediately followed by a stretch
rich in positively charged amino acids (Fig. 2, boxed se-
quence). These features are commonly found in membrane-
spanning domains. The hydrophobic sequences of v-ros are
30 amino acids long, longer than in mcJ3 and longer than is
needed for such a domain.
We wanted to know whether the portion of the mcJ3
cDNA encoding the potential transmembrane domain de-
rived from the human rosi gene or from other parts of the
mcf3 locus. By combined restriction endonuclease analysis,
Southern blotting, and hybridization with synthetic oligonu-
cleotides, two coding exons were localized and sequenced
within the 4.8-kbp EcoRI fragment which contains the
breakpoint in the rosl-derived part of the mcJ3 locus (Fig. 1).
The positions of the deduced splice junctions are included in
Fig. 2. One exon encodes sequences for the putative intra-
cellular domain and for one amino acid of the potential
transmembrane domain. The other encodes sequences from
the potential transmembrane domain and for eight amino
acids of the putative extracellular domain. This last exon is
also found in placental DNA clones containing the human
rosi gene and therefore does not derive from rearranged
sequences (data not shown). Homologs to the eight amino
acids of the putative extracellular domain are not found in
the avian v-ros gene.
There was no consensus structure for cDNA derived from
parts of the gene 5' to the breakpoint found in the 4.8-kbp
EcoRI fragment. The heterogeneity observed in the struc-
ture of the cDNAs probably reflects different splicing pat-
terns of transcripts arising from regions of the mcf3
oncogene which do not derive from rosi. Since we do not
known which, if any, of our cDNA clones reflect transcripts
encoding a transforming protein, we did not analyze these
portions of our cDNA clones. From the position of the
coding region within the cDNA clones and the length of the
longest mcf3 transcript, we estimate the maximal size of an
mcf3-encoded protein to be 75 kilodaltons, of which 50
kilodaltons derive from rosi sequences.
rosi is not rearranged in MCF-7 cells. We showed in the
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ACT ATT ATA
ThrrIie Ile
AGA TTA AAG
Arg Lou Lys
GAG TTG GCT
Glu Lou Ala
ATA CAT ACT
Ile His Thr
CTG ACT CTG
Lou Thr Lou
GTG GAC ATC
Val Asp IIe
GGT TCC ACA
Gly Ser Thr
AAT CAT CCC
Asn His Pro
ATC CTG GAA
Ile Lou Glu
ACG TTT TAT
Thr Phe Tyr
AAA GGC TGT
Lys Gly Cys
TGC CTT GTT
Cys Lou Val
CTC GCC AGA
Lou Ala Arg
GTT CGG TGG
Val Arg Trp
TGG TCT TTT
Trp Ser Phe
CAT TCC AAC
His Ser Asn
AAT TGT CCT
Asn Cys Pro
AGA CCT ACT
Arg Pro Thr
AGC ATT TAT
Ser IIe Tyr
GGT GAA GAT
Gly Glu Asp
GAA ACG AAG
Glu Thr Lys
GAA GAA AAG
Glu Glu Lys
GAA GAG AAG
Glu Glu Lys
GTT GGA ATA
Val Gly lIe
AAT CAA AAA
Aen Gin Lys
GAG CTG CGA
Glu Lou Arg
CTT CCA ACC
Lou Pro Thr
CGT CTC TTG
Arg Lou Lou
TTA GGA GTT
Lou Gly Val
GAC CAG GAG
Asp Gin Glu
AAC ATT CTG
Aen Ile Lou
CTG ATG GAG
Lou Met Glu
GGT CCT TTA
Gly Pro Lou
GTC TAC TTG
Val Tyr Lou
TCC GTG AAA
Ser Val Lys
GAC ATC TAT
Asp Ile Tyr
ATG GCT CCA
Met Ala Pro
GGA ATT CTG
Gly IIe Lou
CTT GAT GTG
Lou Asp Val
GAT GAT CTG
Asp Asp Lou
TTT CAT AGA
Phe His Arg
AAG TCC AGA
Lys Ser Arg
GGC GAT GTG
Gly Asp Val
AAC CGA GAA
Aen Arg Glu
TCT GAG GGT
Ser Glu Gly
GAA CCA CAT
Glu Pro His
TTT CTG GTT
Phe Lou Val
AGT GCC AAG
Ser Ala Lys
GGT CTG GCA
Gly Lou Ala
CAA GAG GAG
Gln Glu Glu
CTG GGA AGT
Lou Gly Ser
GGA AGT GGA
Gly Ser Gly
AAG ATT GAA
Lys Iie Glu
AAG CAG CTT
Lys Gin Lou
GGA GGA GAC
Gly Gly Asp
CTC ACC TTG
Lou Thr Lou
GAA CGG ATG
Glu Arg Met
GAC TAT ACC
Asp Tyr Thr
AAA AAT GAT
Lys Aen Asp
GAA AGT TTG
Glu Ser Lou
ATT TGG GAG
Ile Trp Glu
TTA AAC TAT
Lou Asn Tyr
TGG AAT TTA
Trp Asn Lou
ATT CAG GAC
lie Gln Asp
GAT GAA GCA
Asp Glu Ala
ATT TGT TTG
Ile Cys Lou
GGG TTA AAC
Gly Lou Asn
CCT CTA GGC
Pro Lou Gly
GAT TTT TGG
Asp Ph. Trp
GTT ACA ATC
Val Thr IIe
GAA GGG GTG
Glu Gly Val
GCC GGA GTA
Ala Gly Val
ATT GAA AAT
Ilo Glu Asn
GGA GCC TTT
Gly Ala Phe
GAA ATC AAA
Glu Ile Lys
TTC CTG AAG
Phe Lou Lys
GGA GTT TGT
Gly Val Cys
CTT CTT ACT
Lou Lou Thr
GTT GAC CTT
Val Asp Lou
CAT TTC ATT
His Phe Ile
AGT CCA CGG
Ser Pro Arg
TAC TAT AGA
Tyr Tyr Arg
ATG GAT GGA
Met Asp Gly
ATT TTA ACT
Ile Lou Thr
GTG CAA ACA
Val Gln Thr
ATG ACC CAG
Met Thr Gln
CAA CTT CAG
Gin Lou Gin
AAC AAC AGT
Asn Asn Ser
AAT TCA GAT
Asn Ser Asp
TAT ATG GTA
Tyr Met Val
TCC CAG GAA
Ser Gin Glu
GCA GAC AAA GAT TTC TGC
Ala Asp Lys Asp Phe Cys
TGC CCT TCT GGC AAG CCT GAA GGC CTG AAC TAT GCC TGT
Cys Pro Ser Gly Lys Pro Glu Gly Lou Asn Tyr Ala Cys
ATA CCA GAA ACA
IeI Pro Glu Thr
CCA CTG ACC TTT
Pro Lou Thr Phe
ACA GTG CTT ATA
Thr Val Lou Ile
GGC CTG GCT AAT
Gly Lou Ala Asn
CTT CCT GCC TTC
Lou Pro Ala Phe
GGA GAA GTG TAT
Gly Glu Val Tyr
GTA GCA GTG AAG
Val Ala Val Lys
GAG GCA CAT CTG
Glu Ala His Lou
CTG CTG AAT GAA
Lou Lou Asn Glu
TAT TTG CGT AAA
Tyr Lou Arg Lys
GTA GAC CTG TGT
Vol Asp Lou Cys
CAC AGG GAT CTG
His Arg Asp Lou
ATA GTG AAG ATT
IIe Val Lys IIe
AAG AGA GGG GAA
Lys Arg Gly Glu
ATC TTC ACT ACT
IIe Phe Thr Thr
CTT GGT CAT CAG
Lou Gly His Gin
GGA GGG AGA CTG
Gly Gly Arg Lou
TGC TGG GCT CAA
Cys Trp Ala Gin
TTA TTC AGA AAT
Lou Phe Arg Asn
GGA GTC ATA AAT
Gly Vol IIe Asn
GAC ATT ATG CCA
Asp Ile Met Pro
CTT GCT ACA GAA
Lou Ala Thr Glu
TCT GAA TCT TGT
Ser Glu Ser Cys
CAA GAA AAA CAA
Gin Glu Lys Gin
CTC ACT CAC AGT
Lou Thr His Ser
GAT GGG TCT GAT TAA TAG CGTTGTTTGGGAAATAGAGAGTTGAGATAAACACTCTCATTCAGTAGTTACTGAAA
Asp Gly Ser Asp TER TER
GAAAACTCTGCTAGAATGATAAATGTCATGGTGGTCTATAACTCCAAATAAACAATGCAACGTTCCTGATTTCTAATCTT
GGTTCTGAGAGCCATTTGGTTTCAGTTGTAGCAATCCCCATACCAGCTGCCTGCC
CTT
Lou
AGA
Arg
AAA
Lys
GCA
Ala
AAA
Lys
GCA
Ala
AAG
Lys
TTT
Phe
ATT
I le
GCA
Ala
TCA
Se r
AAT
Asn
GGA
Gly
CCA
Pro
GTA
Va
GCT
Ala
AGA
Arg
CAA
GIn
AAT
Aen
GAA
Glu
ATG
Met
GGT
Gly
AAA
Lye
AGT TTC ATA
So r iPh. I I e
GTC TGG CAT
Val Trp His
AAC GAA GAC
Asn Glu Asp
GCC TGC TAT
Ala Cys Tyr
CCT CGG GAA
Pro Arg Glu
GAA GGA ACA
Glu Gly Thr
ACT TTG AAG
Thr Lou Lys
ATG AGC AAA
Met Ser Lys
CCC CAA TAC
Pro Gin Tyr
GCC CGG ATG
Ala Arg Met
GTA GAT ATT
Val Asp IeI
GCA GCT AGA
Ala Ala Arg
GGA GAC TTT
Gly Asp Phe
GGC CTG CTC
Gly Lou Lou
CAA TCT GAT
Gin Ser Asp
CCT TAT CCA
Pro Tyr Pro
GAG CCA CCA
Glu Pro Pro
GAA CCC GAC
Glu Pro Asp
TTT TTC TTA
Phe Phe Lou
GAA AGC TTT
Glu Ser Phe
GTT GCT TTA
Val Ala Lou
TGT GGC CAA
Cys Gly Gin
GGT CTG AGG
Gly Lou Arg
GTG GCT TAC
Val Ala Tyr
GGA TAT GGA
Gly Tyr Gly
10
30
50
70
90
e10
1 30
1 50
1 70
190
210
230
250
270
290
310
330
350
370
390
41 0
430
450
470
490
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mc f 3 ( 1 )
( 1 5 3 )
mc f 3 ( 57 )
v - r o s ( 2 1 3 )
NFWIPETSFILTIIVGIFLVVT---IPLT-FVWHRRLKNQKSAKEGVTVLINEDKELAEL
* * * * * * ** **** * * * * * ** ****** *
TVTSPDITAIVAVIGAVVLGLTSLTIILTGFVWHQRWKSRKPASTGQIVLVKEDKELAQL
RGLAAGVGLANACYAIHTLPTQEEIENLPAFPREKLTLRLLLGSGAFGEVYEGTAVDILG
** * ********* *** * *** ****** ** * *************** ***
RGMAETVGLANACYAVSTLPSQAEIESLPAFPRDKLNLHKLLGSGAFGEVYEGTALDILA
mcf3 (117) VGSGEIKVAVKTLKKGSTDQEKIEFLKEAHLMSKFNHPNILKQLGVCLLNEPQYIILELM
**** ******* * ***** ************ ** *** *********** *****
v- ros (2713) DGSGESRVAVKTLKRGATDQEKSEFLKEAHLMSKFDHPHILKLLGVCLLNEPQYLILELM
mcf3 (177) EGGDLLTYLRKARMATFYGPLLTLVDLVDLCVDISKGCVYLERMHFIHRDLAARNCLVSV
****** *** ** * ***** ** * * ** ******* * **************
v-ros (333) EGGDLLSYLRGARKQKFQSPLLTLTDLLDICLDICKGCVYLEKMRFIHRDLAARNCLVSE
mcf3 (237) KDYTS-PRIVKIGDFGLARDIYKNDYYRKRGEGLLPVRWMAPESLMDGIFTTQSDVWSFG
* * * * ************************************ ** ** **** **
v-ros (393) KQYGSCSRVVKIGDFGLARDIYKNDYYRKRGEGLLPVRWMAPESLIDGVFTNHSDVWAFG
mcf3 (296)
v-ros (453)
ILIWEILTLGHQPYPAHSNLDVLNYVQTGGRLEPPRNCPDDLWNLMTQCWAQEPDQRPTF
* ** **** **** ** ** * ***** * ***** *** **** * ****
VLVWETLTLGQQPYPGLSN IEVLHHVRSGGRLESPNNCPDD IRDLMTRCWAQDPHNRPTF
mcf3 (356) HRIQDQLQLFRNFFLNSIYKSRDEANNSGVINESFEGEDG...
** ** * * * *
v-ros (513) FYIQHKLQEIRHSPLCFSYFLGDKESVAPLRIQTAFFQPL
FIG. 3. Comparison of deduced amino acid sequences of mc]3 and v-ros genes. The predicted amino acid sequences of the gene products
of mcJ3 and v-ros (17) are shown. The residues shared between mcf3 and v-ros are indicated by asterisks. The numbers to the left refer to
the first amino acid shown in the corresponding line. The end of the v-ros sequence is shown, whereas the mcf3 sequence continues for
another 99 amino acids.
above studies that the mcJ3 gene derives from a rearrange-
ment involving the human rosi gene and that putative
extracellular sequences of this gene have been lost. Since
similar rearrangements have occurred during the biogenesis
of the v-ros (17), v-erbB (32), and trk (14) genes, they are
probably of functional significance. It was thus of interest to
determine whether DNA from the MCF-7 cell line used in
the original cotransformation studies contained the rear-
ranged mcf3 locus or whether this rearrangement was intro-
duced during DNA transfer. The structure of the locus in the
MCF-7 cell line was analyzed by Southern blotting and
compared with either the normal configuration of the locus in
placental DNA or the rearranged configuration in MCF-7-3
and its derived tumors. The probe used for these experi-
ments contained sequences from the 4.8-kbp EcoRI frag-
ment which contains one of the breakpoints introduced
during rearrangement. This probe hybridized to a BamHI
fragment approximately 12 kbp in length in tumor DNAs
containing the rearranged mcJ3 oncogene (Fig. 5, lanes 4 to
6), but hybridized to a band approximately 10 kbp in length
in DNA from MCF-7 cells and from placental DNA (Fig. 5,
lanes 1 and 2). Therefore, we can conclude that the rear-
rangement responsible for the creation of the mcJ3 oncogene
had not occurred in MCF-7 DNA. The alteration is only
found in DNA from MCF-7-3 and its derived tumors and
must therefore have occurred during or after DNA transfer
into NIH 3T3 cells. The blot hybridization studies also
indicate that the mc]3 oncogene is very highly amplified in all
transformed NIH 3T3 cells, a point which we made previ-
ously (8). The activation of the rosi gene was therefore
probably an artifact ofDNA transfer. To test this hypothesis
further, we analyzed RNA from the MCF-7 cell line by
Northern blotting and by RNA protection studies (see Ma-
terials and Methods). We could not detect expression of the
rosi gene in MCF-7 cells. If expressed at all, levels of the
rosl transcript in MCF-7 cells must be 50-fold lower than
levels found in cells transformed with the mcf3 locus. We
conclude that the oncogenic potential of the human rosi
gene may have been activated by rearrangement and gene
amplification occurring during or after gene transfer.
DISCUSSION
We presented data describing the structure of an oncogene
we have called mcJ3 (8). The gene was detected by a
combination of DNA-mediated gene transfer and a
tumorigenicity assay in nude mice. The DNA originally used
in the first transfections came from MCF-7 cells, a human
mammary carcinoma cell line (8). The mc.f3 oncogene was
isolated by molecular cloning, and its structure was com-
pared with the structure of its normal counterpart in human
placental DNA. We found that the mcJ3 oncogene was a
product of a major DNA rearrangement. DNA cotransfec-
tion studies indicated that this rearrangement spanned func-
tionally important domains of mcJ3. The peculiar rearrange-
ment associated with the mcJ3 oncogene was shown to be
present only in DNA isolated from transfected and
FIG. 2. Sequence of common region of mcJ3 cDNA clones. The nucleotide sequence of the common region of the mcJ3 cDNA clones is
depicted. Below the nucleotide sequence, the predicted amino acid sequence is shown. The numbers at the end of each line refer to the
position of the predicted amino acid residues, with position +1 defining the first amino acid of the mcJ3 cDNA which is encoded by the
rosl-derived part of the locus. The potential membrane-spanning domain of 21 hydrophobic amino acids is boxed. The positions of two splicejunctions close to the point of rearrangement are indicated by arrowheads.
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FIG. 4. Southern blot analysis of the human genome with mcjf3
cDNA and v-ros probes. Genomic DNA (10Kg) and DNA (0.1 ng)
from a cosmid clone (3P7) derived from human placental DNA were
digested with EcoRI and analyzed by Southern hybridization under
low-stringency conditions. A fragment from an mcJ3 cDNA clone
encoding amino acids 3 to 150 and a v-ros fragment encoding amino
acids 1 to 305 of the gag-ros fusion protein were used as probes in
panels A and B, respectively. The numbers on the right indicate the
sizes of the DNA fragments of the rosl gene hybridizing to the mcJ3
or v-ros probe. Lanes: 1, DNA from cosmid clone 3P7; 2, DNA from
human placenta; 3, DNA from MCF-7 cells.
tumorigenic cells, but not in the original donor DNA from
the MCF-7 cell line. Since we cannot detect any expression
of the mcJ3 gene in the MCF-7 cells, it seems unlikely that
this gene contributes to the transformed phenotype of
MCF-7. Thus, a functional mcf3 gene was created by a
rearrangement introduced during or after gene transfer. We
have found a second instance of this in an independent line
of experiments (33). Rearrangements and amplifications also
occur in the standard NIH 3T3 focus assay and have been
reported to lead to proto-oncogene activation (26). In our
experience, such events are rare in the focus assay but
common with the cotransformation and tumorigenicity as-
say. The cotransformation and tumorigenicity assay, there-
fore, may be unreliable for the detection of oncogenes in
tumor DNAs. However, it may be a good method for
searching for proto-oncogenes which can be activated by
rearrangement or amplification.
Sequence analysis indicated that mcJ3 was related to the
v-ros gene of the avian retrovirus UR2 (17). Both mcJ3 and
v-ros probes hybridize most strongly to the same DNA
fragment in human DNA, and we therefore designated the
gene from which mcJ3 was derived as rosi. We use this
nomenclature since there may be other ros-related genes in
the human genome. In the human genome, the rosi gene is
localized on chromosome 6, bands qll to q22 (M. Rabin, D.
Birnbaum, M. Wigler, and F. Ruddle, Am. J. Hum. Genet.
37:A36). Translocations of chromosome 6 in this region have
been previously observed in human tumors. Thus, although
rosi is probably not activated in MCF-7 tumor cells, it is
possible that chromosomal alterations affect the rosi locus
and lead to an activation of its oncogenic potential in other
tumor cells. Although most human tumor cell lines, like
MCF-7, do not express detectable levels of rosi, we have
found several human tumor cell lines that do contain signif-
icant levels of rosi transcripts (preliminary data).
The majority of known oncogenes encode proteins with
tyrosine-specific protein kinase activity. However, potential
membrane-spanning domains N terminal to kinase domains
are found only in v-erbB (32), v-fms (9), neu (1), trk (14), and
the v-ros and cellular ros genes (16, 17). The cellular analogs
of the v-erbB and the v-fms genes probably encode the
receptors for the epidermal growth factor and macrophage
colony-stimulating factor, respectively (22, 29). Thus, the
cellular ros gene very likely encodes a hormone receptor as
well. As has been noted before, the tyrosine kinase most
closely related to ros is the insulin receptor (28). In particu-
lar, a stretch of very high (75%) homology to the insulin
receptor exists between positions 245 and 288 in rosi, which
can be aligned with positions 178 to 215 in the cyclic
AMP-dependent protein kinase. Since Cys-198 of the cyclic
AMP-dependent protein kinase is protected from chemical
modification by peptide substrates, this region has been
implicated in substrate binding (5). The high degree of
homology between the amino acid sequences of rosl and the
insulin receptor in this putative substrate-binding domain
might indicate a similar substrate specificity for the tyrosine
kinase activities of these two proteins.
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FIG. 5. Rearrangement of mc]3 locus in MCF-7-3 tumor DNAs.
Genomic DNA (10 ,ug) and cosmid DNA (1 ng) were digested with
BamHI and analyzed by Southern hybridization. A cDNA fragment
encoding amino acids 3 to 150 was used as a probe (see the legend
to Fig. 4). The numbers on the right indicate the sizes of the
fragments in human DNA hybridizing to the cDNA fragment. The
arrowhead indicates the fragment in mouse DNA which hybridized
to the human cDNA fragment. Lanes: 1, DNA from human pla-
centa; 2, DNA from MCF-7 cells; 3, DNA from NIH 3T3 cells; 4,
DNA from the nude mouse tumor MCF-7-3; 5, DNA from the nude
mouse tumor MCF-7-3-1; 6, DNA from the nude mouse tumor
MCF-7-3-1-1; 7 and 8, DNA from cosmid clone 3P7 (see the legend
to Fig. 4); 9, DNA from cosmid clone 115.
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One effect of the rearrangement which created the
oncogenic mcJ3 gene is a deletion of all but eight amino acids
of the putative extracellular domain of rosi. DNA pieces of
unknown origin replaced this part of the rosi gene in the
mcf3 locus. In the v-ros gene the point of fusion between
cellular and viral sequences is located in an analogous
position leading to the loss of most of the putative extracel-
lular domain (16). The deletion of the extracellular domain
may be an important event in the activation of the oncogenic
potential of the rosl gene. Similar events have been ob-
served previously for the v-erbB (32) and the c-erbB (18)
gene in avian leukosis virus-induced erythroblastosis. Inser-
tion of the provirus into the middle of the c-erbB gene leads
to the production of a truncated erbB transcript which
encodes only 64 amino acids of the extracellular domain but
an intact membrane-spanning and intracellular domain.
Similarily, trk seems to have been formed by a somatic
rearrangement that replaced the extracellular domain of a
putative transmembrane receptor with the first 221 amino
acids of a nonmuscle tropomyosin protein (14). We have not
analyzed the nature of the sequences in mcf3 which have
replaced the extracellular domain of the rosi gene. How-
ever, we should be cautious in concluding that the loss of
these extracellular sequences has led to the activation of
rosi. The amino acid sequence of mcJ3 from position 1 to 392
is identical to the deduced coding sequence of rosl as
determined from human placental DNA (H. Matsushime,
L.-H. Wang, and M. Shibuya, personal communication), but
the corresponding coding sequences C terminal to amino
acid 392 have not yet been determined for rosl. Although we
could not detect any gross structural differences between the
DNA of mcJ3 and rosi coding for the C-terminal part of the
protein, we would not have detected any subtle changes
such as point mutations or small deletions by our methods of
analysis. Moreover, the rearranged rosl gene is very highly
amplified in all mcfl-transformed NIH 3T3 cells we exam-
ined. We cannot presently assess the relative contributions
of rearrangement and amplification of this gene to its
oncogenicity.
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